Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Change in Accured Expenses (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Change in Accured Expenses data on record, last reported at -$1.0 million in Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 25.79% year-over-year to -$1.0 million; the TTM value through Sep 2025 reached -$1.0 million, up 79.66%, while the annual FY2024 figure was -$736000.0, 77.14% up from the prior year.
  • Change in Accured Expenses reached -$1.0 million in Q3 2025 per BTAI's latest filing, down from $2.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $9.2 million in Q4 2022 and bottomed at -$4.4 million in Q4 2023.
  • Average Change in Accured Expenses over 4 years is $574000.0, with a median of -$98000.0 recorded in 2022.
  • The widest YoY moves for Change in Accured Expenses: up 304.53% in 2024, down 499.81% in 2024.
  • A 4-year view of Change in Accured Expenses shows it stood at $9.2 million in 2022, then tumbled by 147.34% to -$4.4 million in 2023, then surged by 67.98% to -$1.4 million in 2024, then grew by 25.79% to -$1.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$1.0 million in Q3 2025, $2.3 million in Q2 2025, and -$2.3 million in Q1 2025.